Flexion Phase II data for FX005 gives clinical PoC in arthritis pain
This article was originally published in Scrip
Executive Summary
Flexion Therapeutics reported topline data from a Phase II proof-of-concept study that showed that its lead anti-inflammatory drug candidate FX005 was well-tolerated, provided sustained pain relief and improved joint function for patients with moderate osteoarthritis in the knee.